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Neuroinflammation and oxidative stress have been recognized as common 
aspects in neurodegenerative diseases. Although the inflammatory process may 
induce beneficial effects, such as the elimination of the pathogen, uncontrolled 
inflammation can lead to adverse outcomes through the production of 
neurotoxic factors that exacerbate neurodegenerative disease. Living cells 
continually generate reactive oxygen species (ROS) during energetic 
metabolism. ROS play an important physiological role, however, imbalanced 
defence mechanism of antioxidants, overproduction or incorporation of free 
radicals from environment to living system could be extremely deleterious, 
especially for the central nervous system (CNS). CNS is particularly vulnerable 
to oxidative stress and ROS production has been associated with different 
neurodegenerative diseases. Microglia and astrocytes, as the immune cells in 
the brain, are primary involved in different forms of neurodegeneration. These 
cells in response to a variety of stimuli and pathological events become activated 
and promote the release of inflammatory mediators and ROS. 
Neurodegenerative complications often occur in chronic kidney disease (CKD), 
a condition characterized by a progressive loss of renal metabolic activities and 
glomerular filtration, resulting in retention of solutes, normally excreted by 
healthy kidneys. These compounds, called uremic toxins, accumulate in patients 
with CKD and may have deleterious effects in various physiological functions 
in these patients, such as neurological complications associated to uremic 
syndrome. Indoxyl sulphate (IS) is a protein-bound uremic toxin, poorly 
eliminated by dialytic process, recognized as an uremic nephrovascular-toxin. 
IS has been reported to have effects on different type of cells such as renal 
tubular cells, vascular smooth muscle cells, vascular endothelial cells and 
osteoblasts, but no data regards CNS cells. Because of the mechanism/s 
involved in uremic-toxins induced neurological complications are not 




neuroinflammation and oxidative stress in CNS cells. IS (15-60µM) treatment 
in C6 astrocyte cells increased inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) expression, tumor necrosis factor (TNF-α). 
Moreover IS increased Aryl hydrocarbon Receptor (AhR), Nuclear Factor-kB 
(NF-kB) and inflammasome activation in these cells. In the same experimental 
condition, IS enhanced ROS release and decreased nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) activation, and heme oxigenase-1 (HO-1) and 
NAD(P)H dehydrogenase quinone 1 (NQO1) expression. Similiar observations 
are made in primary mouse astrocytes and mixed glial cells. It has been also 
observed that IS can also affected cell viability and cycle distribution, increasing 
the G0/G1 and S phases and decreasing G2 phase in C6 cells and in astrocytes 
and in mixed glial cells. Moreover neurons incubation with IS (15-60µM) 
induced cell death in a dose dependent fashion. In vivo data indicate that IS (800 
mg/kg, i.p) induced histological changes and an increase in COX-2 expression 
and in nitrotyrosine formation in mice brain. Furthermore preliminary 
experiments on the effect of the human serum on ROS release in C6 cells, 
indicate that IS significantly contributes to oxidative stress in astrocytes. This 
study will be a step towards elucidating if this toxin could be not only a 
biomarker of disease progression in CKD patients, but also a potential 


















Neurodegenerative diseases are a heterogeneous group of disorders chronic and 
progressive, characterized by gradually loss of anatomically or physiologically 
related neuronal systems. While the causes associated with neuronal 
degeneration remain poorly understood, the incidence of neurodegeneration 
increases with age, in mid‑to‑late adult life [1]. This phenomenon, which mainly 
affects elder individuals [2, 3], occurs in neurodegenerative diseases such as 
Alzheimer's disease (AD), multiple sclerosis (MS), Parkinson's disease (PD), 
amyotrophic lateral sclerosis (ALS) following viral infections. The pathological 
features involve the permeability of the blood brain barrier (BBB), the 
destruction of myelin sheath, damage of the axon, the formation of glial scar 
and the presence of inflammatory cells, mostly lymphocytes infiltrated into the 
central nervous sistem (CNS) [4]. The loss of myelin is manifested in clinical 
symptoms together with neuropathic pain, paralysis, muscle spasms and optic 
neuritis [5]. 
The latest report shows that neurodegenerative disorders generate 1% of 
mortality; out of the 11.2% of disability reported worldwide. Life expectancy 
increase in industrialized and developing countries leads to neurological 
disorders and are becoming a major public health problem that could reach 
pandemic proportions in the coming years. It is anticipated that by 2020 the 
levels of disability due to neurological diseases will be above 14.7% [6].  
The most consistent risk factor for developing a neurodegenerative disorder, 
especially AD or PD, is increasing age. Over the past century, the growth rate 
of the population aged 65 and beyond in industrialized countries has far 




the next generations, the proportion of elderly citizens will double, and, with 
this, possibly the proportion of persons suffering from some kind of 
neurodegenerative disorder. 
AD is the most common cause of dementia in people over 65 years of age, and 
is characterized by aggregated protein that forms amyloid plaques and 
neurofibrillary tangles, causing brain atrophy and cognitive impairment 
progression leading to dementia [3]. PD is a long-term degenerative disorder of 
the central nervous system that mainly affects the motor system. Early in the 
disease, the symptoms are shaking, rigidity, slowness of movement, and 
difficulty with walking. Thinking and behavioral problems may also occur. 
Dementia becomes common in the advanced stages of the disease.  
Moreover, the neurodegenerative diseases, including AD and PD, are 
characterized by “redox state” imbalance and chronic inflammation, a major 
cause of cell damage and death [7]. 
 
1.2 Neuroinflammation 
Inflammatory-like responce in the CNS is usually referred as 
neuroinflammation. Neuroinflammation is related to neuronal injury and death 
caused by an inflammatory process, which usually differ from peripheral 
inflammation, due to lack of the classic signals of pheripheral inflammation 
(rubor, tumor, calor and dolor) [8]. Once an immune-privileged site because of 
the presence of the BBB, it is now clear that while peripheral immune access to 
the CNS is resticted and cotrolled, the CNS is capble of dynamic immune and 
inflammatory responses to a variety of insults [9]. Infections, trauma, stroke, 
toxins and other stimuli are capble of producing an immediate and short lived 








Figure 1.1: Innate immunity in the periphery and CNS. Resident microglia 
and astrocytes exert multiple functions in the CNS, including protective and 
restorative responses to CNS infection or injury. Cytokines and chemokines 
expressed by resident CNS cells also promote the recruitment of circulating 
lymphocytes and myeloid cells from the periphery to assist in pathogen 
clearance. Innate responses in the CNS cannot directly initiate adaptive 
immunity. Innate CNS reactions also occur during neuroinflammatory 




The discipline of pathology makes a fundamental distinction between acute and 
chronic inflammation. In general, an acute neuroinflammatoy response is 
beneficial to the CNS, since it contributes to repair the damaged tissue and to 
minimize further injury. This response includes activation of the resident 
immune cells (microglia) resulting in a phagocytic phenotype and the release of 
inflammatory mediators such as cytokines and chemokines [11]. While an acute 
insult may trigger oxidative and nitrosative stress, it is typically short-lived and 
unlikely to be detrimental to longterm neuronal survival. In contrast, chronic 
neuroinflammation is a long-standing and often self-perpatuating 
neuroinflammatory response that persist long after an initial injury or insult [12]. 




microglia and subsequent release of inflammatory mediators, but also results in 
increased oxidative and nitrosative stress [11]. The sustained release of 
inflammatory mediators works to perpetuate the inflammatoy cycle, activating 
additonal microglia, promoting their proliferation, and resulting in further 
release of inflammatory factors. Owing to the chronic and sustained nature of 
the inflammation, there is often compromised of the BBB which increases 
infiltration of periphral macrophages into the brain parenchyma to further 
perptuate the inflammation [9]. The neuroinflammatory process involves not 
only infiltrating immune cells and microglia, but also astrocytes and neurons. In 
response of injury or disease, all these cells can produce inflammaory mediators 
including: cytokines (tumor necrosis factor-α, TNF-α; interleukin 1β, IL-1β and 
interleukin-6, IL-6), prostaglandins, reactive oxygen species (ROS) and 
nitrogen species and complement proteins. These proinflammatory and 
neurotoxic factors induce the expression of othr cytokines, chemokines and 
adesion molecules causing further glial activation [13]. 
It is chronic inflammation that is typically associated with neurodegenerative 









Figure 1.2: Two faces of neuroinflammation. Chronic inflammation is an 
important feature in the progressive of neurodegeneration. 
Neuroinflammation is an active process and may therefore be beneficial or 






1.3 Oxidative stress in brain 
Oxygen is vital for all living cells whether neuronal or other kinds of cells taking 
part in tissue formation but on the other hand it is potentially dangerous in 
excess. ROS are widely recognized as key mediators of cell survival, 
proliferation, differentiation, and apoptosis. Hydrogen peroxide is generated by 
a number of systems, including reactions catalyzed by monoamine oxidases A 
and B with a described location of neuronal and glial mitochondrial membranes. 
Oxidative stress has been implicated in the pathogenesis of brain desorders, 
mainly neurodegenerative desorders and ischemia (Figure 1.3) [15]. The brain 
is particulary vulnerable to oxidative damage because it has an elevated oxygen 
consumption, high levels of polynsaturaded fatty acids, low levels of 
antioxidants and relatively high levels of redox transition metal ions [16]. A 
major reason for the high O2 uptake by the brain is the vast amounts of adenosine 
triphosphate (ATP) needed for its normal activity (4 x1012 ATP molecules every 
minute). The large amount of ATP is necessary to maintain neuronal 
intracellular ion homeostasis in face of all the openings and closings of ion 
channels associated with propagation of action potentials and neurosecretion. 
Neuronal membranes are packed with phospholipids containing 
polyunsaturated fatty acid esters, which are very sensitive to attack of ROS, 
causing a chain reaction which generates lipid radicals and extensive membrane 
damage. Brain antioxidant defenses are modest. In particular, the brain contains 
less catalase, glutathione peroxidase and vitamin E. In brain, the oxygen-rich 
enviroment and the presence of iron ions facilitate the production of ROS, such 
as the superoxide anion (O2
.-) and hydrogen peroxide that trigger a cascade of 
oxidative events [16]. Stressful or pathogenic conditions may trigger oxidative 
stress by unbalancing oxidant production pathways and anti-oxidant defences, 
leading to increased ROS level. These reactive species may interact with 
proteins, lipids, carbohydrates and nucleic acids, leading to oxidative damage 




that brain cells, like microglia and astrocytes, induce and release inflammatory 
mediators in response to oxidative stress [18, 19]. In addition, ROS act as a 
critical signaling molecule to trigger inflammatory responses in CNS through 
the activation of the redox sensitive transcription factors, including Nuclear 





Figure 1.3: Oxidative stress and inflammation can damage nerve cells 
neurons loss of brain nerve cells. Nerve cells in the brain are organized and 
networked to perform various different tasks. Chronic oxidative and 
inflammatory stress can progressively damage those nerve cells as well as 









1.4 Cells mediators of neuroinflammation and oxidative stress 
Microglia and astrocytes are two major types of glial cells involved in the 
regulation of the immune response to pathological processes in the brain [22]. 
Functional activation of microglia and astrocytes and the resulting 
neuroinflammation are associated with infection, autoimmunity, and 
pathogenesis of neurodegenerative diseases. In response to lead exposure, 
microglia and astrocytes can increase the production and release of 
inflammatory cytokines, enhance ROS generation, impede antioxidant activity, 
and result in neuronal injury or neuronal loss in the brain or other parts of the 
CNS [23, 24].  
Microglia are the resident tissue macrophages in the CNS and are the principal 
mediators of inflammation and oxidative stress (Figure 1.4). Microglia represent 
approximately 5-10% of total cell popolation of the adult brain [25]. They assist 
in the remodeling and maturation of the brain and support clearance of cell 
remnants after apoptosis. In the resting state microglia display a small cell soma 
and numerous branching process (a ramified morphology). In healthy brain 
tissue, these processes are dynamic structures that extend and retract sampling 
and monitoring their microenviroment. During the resting state several key 
surface receptors are expressed at low levels; these include the tyrosine 
phosphatase (CD)45, CD-14 and CD11b/CD18. In presence of an activating 
stimulus, microglial cell-surface receptor expression is modified and the cells 
change from monitoring role to one of protection and repair [12]. Activated 
microglia secrete a variety of inflammatory mediators including cytokines 
(TNF-α, and interleukins IL-1β and IL-6) and chemokines (macrophage 
inflammatory protein MIP-1α, monocyte chemoattractant protein MCP-1 and 
interferon (IFN) inducible protein IP-10) that promote the inflammatory state. 
The morphology of the cells changes from ramified to amoeboid as they take on 
a phagocytic role. These moderately active microglia are thought to perform 




cellular debris, and secreting trophic factors that promote neuronal survival. 
Persistent activation of brain-resident microglia may increase the permeability 
of the BBB and promote increased infiltration of peripheral macrophages, the 
phenotype of which is critically determined by the CNS environment [26]. 
Microglia are the critical convergence point for the many diverse triggers that 
elicit an adaptive immune response. Stroke, hypoxia, and trauma compromise 
neuronal survival and indirectly trigger neuroinflammation as microglia become 
activated in response to the insult in an attempt to limit further injury. Infectious 
agents and the exposure to neurotoxins activate microglia. Microglial responses 
to these toxins may contribute to neuronal dysfunction and eventually hasten 
neurodegeneration [12]. 
Astrocytes are specialized glial cells that represent 35% of the total CNS cell 
population (Figure 1.4). In physiological conditions, astrocytes carry out several 
functions thar involve the control of neuronal function. Astrocytes are essential 
for brain homeostasis, as they provide metabolites and growth factors to 
neurons, support synapse formation and plasticity, and regulate the extracellular 
balance of ions, fluid and neurotransmitters [27]. Thanks to their strategic 
location in close contact with CNS-resident cells (neurons, microglia, 
oligodendrocytes and other astrocytes) and blood vessels, astrocytes participate 
in BBB maintenance and permeability. They also play a role in the control of 
immune cell trafficking and activation. Astrocytes are immune-competent cells 
able to detect danger signals, respond via secretion of cytokines and 
chemokines, and activate adaptive immune defense [28]. However, microglia 
can become activated to produce H2O2, and cytokines such as interleukin (IL)-
1, IL-6, and TNF-α. Subsequently such cytokines can cause microglia to 
generate more ROS and to produce inducible nitric oxide synthase (iNOS) and 
hence excess of NO (nitric oxide). Cytokines can additionally be produced by 
activated astrocytes, and the latter may again respondto cytokines by iNOS 




inflammation. CNS injury triggers a process leading to scar formation, whose 
impact on tissue homeostasis is ambivalent, as inflammatory and neurotoxic 
mediators are produced at injury site but remain confined to that area thanks to 
the glial scar. 
 
 
Figure 1.4: Astrocyte and microglia cells. The neuroglia are the non-neuronal 
cells of the central nervous system and play a crucial role in the development 
and maintenance of the neurons that they support. Microglia contain branched 
cytoplasmic processes and function as the macrophages of the CNS and play 
an important phagocytic role. Astrocytes are supporting cells within the CNS 
that have numerous functions including providing structural support, 
insulating receptive surfaces, and buffering the extracellular compartment. 
Also, during inflammation and injury, they divide and wall off damaged areas 
[29]. 
 
Astrocytes, as well as microglia, display an array of receptors involved in innate 
immunity, including Toll-like receptors (TLRs), nucleotidebinding 
oligomerization domains, double-stranded RNA dependent protein kinase, 




common feature of a variety of neurodegenerative disorders is the presence of a 
large number of activated glial cells including astrocytes and microglia that 
involve the changes of morphology and expression of many inflammation-
related proteins. Gliosis, especially astrogliosis, is characterized by astrocytic 
proliferation, extensive hypertrophy of the cell body, and functional changes, 
when stimulated with various factors including Lipopolysaccharide from E. coli 
(LPS), IL-1𝛽, TNF-𝛼 [30,31]. Most studies have demonstrated that microglial 
cells play an important role in neuroinflammation and neurodegeneration, 
accumulating evidence has also demonstrated the characteristic changes of 





Figure 1.5: How direct neurotoxic insults or inflammatory triggers can 
generate a vicious cycle of cytotoxic and stimulatory factors that leads to low-









































2.1 Chronic kidney disease (CKD) 
Chronic kidney disease (CKD) is a general term for heterogeneous disorders 
affecting the structure and function of the kidney (Figure 2.1). CKD is 
recognized as a major health problem affecting approximately 13% of the 
United States population [33] and the numbers are expected to continue to 
climb.1: infact the number of patients with kidney failure treated by dialysis and 
transplantation has increased dramatically in the United States from 209000 in 
1991 to 472000 in 2004 [34]. 
 
 
Figure 2.1: Normal kidney vs. diseased kidney. A normal kidney has about 1 
million filtering units. Each unit, called a glomerulus, connects to a tubule, 
which collects urine. Conditions such as CKD take a toll on kidney function by 





The definition of CKD is based on the presence of kidney damage (ie, 
albuminuria) or decreased kidney function, quantified by measured or estimated 
glomerular filtration rate (GFR <60 mL/min per 1·73 m²) that persists for 3 
months or more [36, 37]. 
Because of the central role of GFR in the pathophysiology of complications, the 
disease is classifed into five stages on the basis of GFR (Figure 2.2): 
• Stage 1: normal GFR ≥ 90 mL/min per 1.73 m2 and persistent albuminuria 
• Stage 2: GFR between 60 to 89 mL/min per 1.73 m2 
• Stage 3: GFR between 30 to 59 mL/min per 1.73 m2 
• Stage 4: GFR between 15 to 29 mL/min per 1.73 m2 










The prevalence of these stages of CKD in the US population is as follows: 1.8% 
for stage 1, 3.2% for stage 2, 7.7% for stage 3 and 0.35 % for stages 4 and 5. 
Patients with stage 3 or 4 disease progress to end stage renal disease or stage 5 
at a rate of 1.5% per year. Stage 1 or 2 CKD patients progress to more advanced 
stages at approximately 0.5% per year 5. 
Stage 5 CKD is often called end-stage kidney disease, end-stage renal disease, 
or end-stage kidney failure, and is largely synonymous with the now outdated 
terms chronic renal failure or chronic kidney failure; and usually means the 
patient requires renal replacement therapy, which may involve a form of 
dialysis, but ideally constitutes a kidney transplant.  
Kidney failure is traditionally regarded as the most serious outcome of CKD 
and symptoms are usually caused by complications of reduced kidney function. 
When symptoms are severe they can be treated only by dialysis and 
transplantation; kidney failure treated this way is known as end-stage renal 
disease. Kidney failure is defined as a GFR of less than 15 mL/min per 1·73 m², 
or the need for treatment with dialysis or transplantation. Other outcomes 
include complications of reduced GFR, such as increased risk of cardiovascular 
disease, acute kidney injury, infection, cognitive impairment, and impaired 
physical function [39, 40]. Complications can occur at any stage, which often 
lead to death with no progression to kidney failure, and can arise from adverse 
effects of interventions to prevent or treat the disease. 
In developed countries, CKD is generally associated with old age, diabetes, 
hypertension, obesity, and cardiovascular disease, with diabetic 
glomerulosclerosis and hypertensive nephrosclerosis as the presumed 
pathological entities; however, exact diagnosis is often difficult. Diabetes is the 
most prominent cause of CKD, accounting for 33% of adult CKD cases [41]. 




the course of their disease; therefore, as the number of diabetic patients 
increases, the incidence of CKD can be expected to follow. 
Diabetic glomerulosclerosis is characterised by slowly worsening albuminuria, 
hypertension, and progressive decline in GFR, sometimes with nephrotic 
syndrome. Hypertensive nephrosclerosis is associated with addition signs of 
hypertensive end-organ damage because of long periods of poorly controlled 
hypertension. Hypertensive nephrosclerosis has no distinct markers of kidney 
damage, but highnormal to high concentrations of albuminuria can occur after 
the onset of decreased GFR. Many patients with diabetes and CKD do not have 
typical features of diabetic glomerulosclerosis, and pathological findings of 
hypertensive nephrosclerosis are often more severe than expected because of 
the level of blood pressure. Atherosclerotic renovascular disease is suggested 
by a sudden worsening of hypertension, with findings of atherosclerosis in non-
renal areas. Renal ultrasound may show asymmetrical kidney sizes, with the 
smaller kidney receiving less blood supply because of its renovascular disease. 
Vascular disease (primarily hypertension) is the second most common cause of 
CKD and it includes large vessel disease such as bilateral renal artery stenosis 
and small vessel disease such as ischemic nephropathy, hemolytic-uremic 
syndrome, and vasculitis. The presence of red-blood-cell or white-bloodcell 
casts, or specific imaging abnormalities, suggest another cause of kidney 
disease. In developing countries, common causes of CKD also include 
glomerular and tubulointerstitial diseases resulting from infections and 
exposure to drugs and toxins. 
About one in ten people suffer from CKD. African Americans are at greater risk 
due to a prevalence of hypertension among them.  
People with high blood pressure and diabetes are also at high risk of suffering 
from CKD than those people without these underlying conditions. About one of 




Other health conditions that may lead to CKD are obesity, high cholesterol, a 
family history of the disease, lupus, and other forms of cardiovascular diseases. 
CKD was the cause of 956,000 deaths globally in 2013, up from 409,000 deaths 
in 1990. Studies have shown a true association between history of CKD in first- 
or second-degree relatives, and risk of disease [42]. In addition, African 
Americans may have higher serum levels of human leukocyte antigens (HLA) 
[42]. High HLA concentrations can contribute to increased systemic 
inflammation, which indirectly may lead to heightened susceptibility for 
developing kidney disease. Lack of nocturnal reduction in blood pressure 
among groups of African Americans is also offered as an explanation [42], 
which lends further credence to a genetic etiology of CKD racial disparities. 
 
2.1.1 Uremic complications 
The prevalence of the complications of CKD increases with each stage of the 
disease. As reported by National Kidney Foundation [41], many of the disorders 
associated with uremia are generally asymptomatic and can first be identified at 
GFRs of less than about 60 mL/min per 1x73 m². These disorders are more 
common as GFR declines, and when GFR is 15–30 mL/min per 1x73 m². The 
main complications are: cardiovascular (hypertension); hematologic (anaemia); 
endocrine (hyperparathyroidism), hyperphosphataemia and acidosis and 
hypocalcaemia and neurologic (dementia, pheripheral neuropathy; Figure 2.3) 
[43]. Fatigue, weakness, frailty, and decreased health-related quality of life are 


























Figure 2.3: Uremic complications in CKD [44]. 
 
 
Impairments in renal excretory and endocrine function parallel reductions in 
GFR, leading to complex disorders that are characterised by solute retention, 
hormone deficiencies or resistance, and compensatory responses in other organ 
systems [45]. 
The increased cardiovascular risk associated with end stage renal disease has 
been well established, and estimated cardiovascular mortality rates are ten to 
one hundred fold higher among dialysis patients than age- and sex-matched 




Hypertension is a traditional cardiovascular risk factor and is attributed to salt 
retention and increased vascular tone due to a failure to suppress the sympathetic 
nervous system and renin-angiotensin system, inhibition of sodium-potassium 
ATPase, and NO deficiency. Hypertension contributes to the cardiovascular risk 
associated with CKD. Szcech and coworkers demonstrated that patients with 
hypertension are at increased risk for new or recurrent cardiovascular events in 
individuals with stage 2–3 CKD [47]. Diabetes is associated with adverse 
outcomes in all stages of CKD [48]. 
The presence of left ventricular hypertrophy (LVH), a complication which 
increases in relation to progressively lower levels of eGFR, is also a 
cardiovascular risk determinant in CKD patients. Anemia and hypertension, are 
two CKD associated complications hypothesized to play a role in the 
development of LVH [49]. 
Abnormal serum phosphate levels, calciumphosphate ion product, and 
parathyroid hormone levels are independent cardiovascular risk factors in the 
setting of stage 5 CKD [50]. Higher calcium–phosphate products and the 
cumulative dose of oral calcium-based phosphate binders correlate with the 
extent and progression of arterial calcification in dialysis and stage 3 or 4 CKD 
patients Interestingly, serum phosphate levels were associated with increased 
rates of death and myocardial infarction in patients with stage 3 or 4 CKD [51]. 
This suggests that arterial calcification results in clinical morbidity and 
mortality in this patient population. Poorly controlled metabolic bone disease 
contributes to vascular calcification, which promotes arteriolosclerosis and 
increases vascular wall stiffness.  
Anemia is defined as a reduction in one or more of the major red blood cell 
measurements; hemoglobin concentration, hematocrit, or red blood cell count. 
A normochromic, normocytic anemia usually accompanies progressive CKD 
[52] and there is a strong correlation between the prevalence of anemia and the 




diagnosing and managing anemia in CKD patients. While anemia in CKD can 
result from multiple mechanisms (iron, folate, or vitamin B12 deficiency; 
gastrointestinal bleeding; severe hyperparathyroidism, systemic inflammation, 
and shortened red blood cell survival), decreased erythropoietin synthesis is the 
most important and specific etiology causing CKD-associated anemia. 
Erythropoietin is a glycoprotein secreted by the kidney interstitial fibroblasts 
and is essential for the growth and differentiation of red blood cells in the bone 
marrow. In CKD, tubular atrophy generates tubulointerstitial fibrosis, which 
compromises renal erythropoietin synthetic capacity and results in anemia [53]. 
The anemia of CKD increases morbidity and mortality from cardiovascular 
complications (angina, left ventricular hypertrophy and worsening heart 
failure), which may lead tofurther deterioration of renal function and the 
establishment of a vicious cycle termed the “cardiorenal anemia syndrome” 
[52]. The anemia of CKD is treated via recombinant human erythropoietin.  
Mineral and bone disorders in CKD are characterised by abnormalities in serum 
concentrations of calcium, phosphorus, 1,25-dihydroxycholecalciferol, and 
parathyroid hormone; abnormalities in bone morphology; and vascular 
calcification. Renal osteodystrophy is the spectrum of histological changes, 
which occur in bone architecture of patients with CKD. The kidney is the 
primary site for phosphate excretion and 1-α-hydroxylation of vitamin D. CKD 
patients develop hyperphosphatemia as a result of inadequate 1,25 dihydroxy-
vitamin D levels that reflect reduced synthesis from parenchymal scarring. In 
addition, renal phosphate excretion is reduced. Together both processes cause, 
serum calcium levels to fall resulting in increased secretion of parathyroid 
hormone (secondary hyperparathyroidism). Parathyroid hormone has a 
phosphaturic effect. It also increases the calcium levels by increasing bone 
resorption and promoting 1-α-hydroxylation of 25-hydroxy vitamin D 




Acidosis, the suppressive effect of phosphate retention on renal synthesis of 1, 
25 dihydroxyvitamin D synthesis, and absence of the physiologic inhibitory 
effect of vitamin D on parathormone secretion are also minor factors that 
contribute to the low turnover bone disease in CKD patients [54]. CKD-
associated mineral bone disorders significantly increase mortality in CKD 
patients.  
Dyslipidemia is a major risk factor for cardiovascular morbidity and mortality 
and is common among patients with CKD. In general, the prevalence of 
hyperlipidemia increases as renal function declines, with the degree of 
hypertriglyceridemia and elevation of LDL cholesterol being proportional to the 
severity of renal impairment. 
Several factors contribute to the development dyslipidemia associated with 
chronic renal impairment. Hypercholesterolemia in nephrotic syndrome is 
thought to be due to increased production and decreased catabolism of 
lipoproteins.  
As patients progress through the stages of CKD, nutritional requirements are 
altered and metabolism of protein, water, salt, potassium, and phosphorous are 
affected [55]. These changes lead to ineffective energy generation despite 
adequate intake of protein and carbohydrate substrates. In more extreme 
manifestations, these alterations in nutrient utilization cause “uremic 
malnutrition,” a syndrome that is distinct from malnutrition caused by 
inadequate nutrient intake. 
Inflammation is a non-traditional risk factor believed to play a role in mediating 
cardiovascular risk in CKD. Markers of inflammation are often elevated in CKD 
patients and are predictive of cardiovascular risk in this population [56]. The 
chronically activated immune system in uremia leads to a chronic low-grade 
inflammation, and consequently to atherosclerotic cardiovascolar diseases [56] 
CKD patients present a chronically activated immune system, but on the other 




infection. Uremia-related immune dysfunction is a complex interaction between 
the innate and adaptive systems, in which immune activation and immune 
suppression coexist. On the one hand, as consequence of tissue damage, the 
innate immune system is triggered, and although inflammation is an essential 
response to eliminat aggressors, it can be considered a double-edged sword 
when the initial reaction is not limited. During inflammation, vasodilatation, 
vascular permeabibly, movement of inflammation cells, and activation of cells 
of the immunesystem are increased. In addition, acute-phase reactants can be 
produced, as can complement components, fever, and activation of systemic 
immunity. Therefore, to avoid tissue damage, inflammatory responses must be 
well organized and controlled by inflammatory mediators, as cytokines, 
proteases, prostaglandins, leukotrienes and vasoactive molecules [57]. On the 
other hand, regarding poor responce to infectious challenges, recent data have 
proposed that innate immunity, plays an important role. Firstly, th main cause 
of infactions in CKD is bacteria [58]. Reduce killing capabilities, modulated 
spontaneuos apoptosis of neutrophilis [59] and inhibited NO syntesis by 
macrophages have been described in the presence of uremia. Oxidative stress, 
as well as inflammation is crucial for the defense against infections and 
increases in parallel with the progression of CKD. Furthermore, the antioxidant 
systems are severely impaired in CKD patients and worsen progressively with 
the degree of renal failure. 
 
2.1.2 Cognitive impairment in CKD 
CKD is frequently associated with cognitive impairment: 17–50 % of all 
patients with CKD present with executive, memory and language deficits, 
depending on the stage of kidney disease [60-62]. Among patients with terminal 
CKD receiving hemodialysis, more than 85 % had cognitive deficits [63]. The 
neurological disease in CKD includes cognitive slowing, attention deficits, 




memory deficits, language (particularly disturbances in naming and word 
fluency) deficits. Cognitive deficits have direct relevance for daily function in 
CKD patients and contribute largely to the morbidity and mortality in these 
patients [64].  
In patients with renal failure, encephalopathy is a common problem that may be 
caused by uremia, thiamine deficiency, dialysis, transplant rejection, 
hypertension, fluid and electrolyte disturbances or drug toxicity [65]. In general, 
encephalopathy presents with a symptom complex progressing from mild 
sensorial clouding to delirium and coma. It is often associated with headache, 
visual abnormalities, tremor, asterixis, multifocal myoclonus, chorea and 
seizures [65]. 
Dementia is more common in patients with renal failure than in the general 
population. The incidence of dementia in aged patients undergoing dialysis is 
estimated at 4.2%, with predominant occurrence of multi-infarct dementia 
[66,67]. Dementia should be differentiated from delirium and depression, which 
are also common problems in renal failure. Subacute and fast progressive 
dementia can occur in progressive multifocal leukoencephalopathy and dialysis 
dementia. Cerebral atrophy is common in patients with chronic renal failure, 
even in patients without evident cognitive, affective or behavioural changes. 
Cerebrovascular disease is a predominant cause of morbidity and mortality in 
patients with CKD. This population is prone to the development of 
atherosclerosis and ischemic stroke. But the presence of several risk factors also 
predisposes to hemorrhagic complications. Ischemic stroke in renal failure 
mainly results from atherosclerosis, thromboembolic disease or intradialytic 
hypotension. Atherosclerosis in patients with CKD is generally more diffuse 
and distally located than in the general population, probably because of 
combination of traditional atherogenic risk factors such as male gender, age, 
diabetes mellitus, hypertension, dyslipidemia and smoking with factors more 




Movement disorders in patients with renal failure can occur as a result of 
encephalopathy, medication or structural lesions. Several types of involuntary 
movements can occur in metabolic encephalopathy. Asterixis or “flapping 
tremor” is probably caused by sudden loss of tonus, originating from cortical 
dysfunction and clinically consists of multifocal action-induced jerks that can 
even mimic drop attacks in severe cases [69].  
Neurological infections in patients with renal failure mainly present as acute, 
subacute or chronic meningitis, encephalitis, myelitis or brain abscess [70]. 
Infection with cytomegalovirus is the most frequent opportunistic infection 
following renal transplantation. The immunosuppressive state of patients with 
renal failure not only predisposes to infection with opportunistic pathogens, but 
is also associated with an increased incidence of de novo neoplasia.  
Although development of neoplasms in the neurologic system is rare, malignant 
meningioma [71] and primary central nervous system lymphoma have been 
described in end stage renal failure [72].  
 
2.2 Uremic Toxins 
The uremic syndrome is characterized by the retention of various solutes that 
would normally be excreted by the kidneys. These compounds are called uremic 
called uremic retention solutes, or uremic toxins and they interact negatively 
with biologic functions [73].  
In the past years, research on uremic toxicity resulted in the identification of 
dozens of retention solutes. In 2003, the European Uremic ToxinWork Group 
(EUTox) proposed a classification of 90 retention solutes providing data on 
normal and pathologic serum concentrations [73]. In 2007, results were further 
discussed and expanded with the addition of 14 solutes [74,75]. More recently, 
scientific and technological progress resulted in the identification of many new 




The most common classification, given by EUTox discriminates these solutes 
according to molecular weight (MW), to the ability to bind the proteins and to 
the removal pattern by dialysis process, into three groups: 
 
1. Low-Molecular-Weight Water-Soluble Uremic Toxins. This group 
consists of small molecules (molecular weight <500 Da) that are soluble 
in water and easily removed by any dialysis strategy. Low-molecular-
weight organic compounds may occur in free water-soluble form or 
bound to plasma proteins, which alters the function of both the toxin and 
the transporter protein. Of the 90 molecules evaluated by EUTox, 68 
were found to be members of this group, the most common compounds 
being ADMA (asymmetric dimethylarginine), creatine, creatinine, 
hyaluronic acid, guanidine, guanidinoacetate, guanidinosuccinate, 
oxalate, SDMA (symmetric dimethylarginine), urea and uric acid.  
2. Middle-Molecular-Weight Molecules. The molecular mass of middle-
molecular-weight molecules is above 500 Da. Members of this group 
include adiponectin, cystatin C, leptin, motilin, α1-acid glycoprotein, 
α1-microglobulin, endothelin, ghrelin, osteocalcin, β2-microglobulin. 
3. Protein-Bound Solutes. This grup included protein-bound solutes. 
Although the molecular weight of most members of this group is less 
than 500 Da, because of their protein-binding capacity they are 
recognized as ‘difficult to remove’ by dialysis. The main protein-bound 
solutes include: advanced glycation end products (AGEs), carboxy 
methyl propyl furanpropionic acid, cytokines, interleukins, TNF-α, 
dimethylguanidines, hippuric acid, homocysteine, indole-3-acetic acid, 
indoxyl glucuronide, indoxyl sulfate, kynurenic acid, kynurenine, leptin, 
phenolic compounds, p -cresyl sulfate, p -cresyl glucuronide, phenol 





The gradual accumulation of retained uremic toxins results in uremic illness, 
which accompanies the progressive loss of kidney function [78]. Numerous 
signs and symptoms are associated with uremic illness, including anorexia, 
lethargy, decreased mental acuity, itching, nausea, sleep disturbance, and sexual 
dysfunction. Accumulation of uremic toxins has also been associated with 
progression of CKD, adverse cardiovascular outcomes, and mortality. 
It has been suggested that uremic toxins promote progression of renal failure by 
damaging tubular cells and their overload accelerates the loss of kidney 
function, glomerular sclerosis and tubulointerstitial injury [78,80]. 
The liver and kidneys together comprise an organ system responsible for the 
removal of toxic compounds from the body. Renal function loss in patients with 
cirrhosis has been associated with a worse prognosis. 
Studies investigating the phatophysiology of neurological disease in CKD have 
tended to focus on the hypothesis that ore more of these retained toxins is 
responsable for mediating the neurological dysfunction and cerebral endothelial 
dysfunction [81]. Uremic toxins in CKD may modulate lung dysfunction, 
susceptibility to lung injury [82]. Several studies have postulated that middle 
molecules are the toxins that underlie the developement of neurological 
disfunction in CKD [83]. 
 
2.2.1 Indoxyl Sulphate (IS) 
Indoxyl sulfate (IS) is a solute that accumulates in the serum of CKD patients. 
Originally called “indican,” it was first isolated by Obermayer and Popper in 
1911 and noted to be present in high concentrations in the blood of CKD 
patients. IS is a small solute (MW 213) and is at least 90% bound to plasma 
proteins (Figure 2.4). Being bound to proteins affects the dialytic behavior of 
IS. Vanholder and coworkers [84] proposed that the protein binding of IS 
limited its clearance, because the plasma levels of IS declined less than urea 




membrane [85-87]. Protein-bound solutes exist in rapid equilibrium between the 
bound and free, unbound state. As IS passes through capillaries surrounding the 
proximal tubules, the unbound solute is taken up in tubule cells by organic anion 
transporters (OAT1 and OAT3) located on the basolateral membrane [88,89]. It 
then passes into the tubular lumen through apical membrane transporters [90]. 
As an unbound IS molecule is secreted, another molecule will dissociate from 




Figure 2.4: IS chemical structure [91]. 
 
IS is derived from dietary tryptophan that reaches the colon is converted to 
indole by by gut microbiota tryptophanase (TnaA) action and absorbed into the 
systemic circulation. Indole is then oxidized to indoxyl by cytochrome p450 
(CYP)-2E1, and sulphated by sulphotransferase (SULT)-1A1 to IS, in the liver 
(Figure 2.5). IS subsequently reaches the bloodstream is taken up into the 
tubular cells by basolateral multispecific organic anion transporters (OATs), 
especially OAT1 and OAT3, and then excreted from the kidney through tubular 
secretion [92]. 
Diet also plays an important role in the production of IS. As IS is derived from 
breakdown of tryptophan, higher dietary protein intake increases its production. 




weeks had greater IS level and urinary excretion than those who consumed a 
low protein diet. In addition, subjects who consumed vegetarian diets had lower 




Figure 2.5: IS production and accumulation in CKD. Dietary tryptophan is 
converted to indole, by gut microbiota action. Indole is then oxidized to 
indoxyl by cytochrome p450 (CYP)-2E1, and sulphated by sulphotransferase 
(SULT)-1A1 to IS, both in the liver. During CKD, IS is unable to be excreted 
in the urine, and therefore accumulates in serum. IS accumulation is 
associated with increased progression of kidney damage [94]. 
 
 
While IS is normally excreted into urine, in uremia the inadequate renal 
clearance of IS leads to an elevation of it [87]. The clearance value of IS in 
normal human is 3023±533 mL/min/1.73 m2, which is 22±4 times of creatinine 




normal 0.53± 0.29 mg/L) and free IS (uremic patients 3.22±1.21mg/L vs. 
normal Not Detected) increases significantly in uremic patients [72]. 
Multiple studies have suggested that IS is toxic, having both renal and non-renal 
effects. It has been most extensively identified as a contributor to renal disease 
progression and vascular disease [87].  
IS has been reported to injure the proximal tubule cells. As IS accumulates in 
the plasma with renal insufficiency, the level in the proximal tubule cells 
presumably rises and causes injury. The accumulation of IS, infact, generates 
free radicals, reduces superoxide scavenging activity, and consequently causes 
tubular cell injury by impairing the kidney’s anti-oxidative systems [96]. 
The damaged tubular cells produce transforming growth factor (TGF-b1) as 
well as chemokines such as intercellular adhesion molecule-1 (ICAM-1), 
monocyte chemoattractant protein-1 (MCP-1), osteopontin and endothelin-1 
(ET-1). These chemokines promote the infiltration of macrophages. The 
secreted TGF-b1 stimulates the production of TIMP-1 and collagen. The 
damaged tubular cells are transformed into myofibroblasts through an 
epithelial-to-mesenchymal transition induced by TGF-b1, these changes 
facilitate interstitial fibrosis. IS accumulated in uremic serum accelerates tubular 
cell injury and induces subsequent interstitial fibrosis, thus acting as a 
nephrotoxin [87]. 
A series of studies by Niwa [87] tested the effect of oral IS administration on 
renal injury in rats with 5/6th nephrectomies. Compared to control, rats orally 
fed IS increased glomerular sclerosis. In proximal tubule cell culture studies, IS 
induces inflammation and fibrosis. 
IS is thought to injure the vasculature through various mechanisms. Dou and 
coworkers [97] showed that IS impairs the proliferation and repair of human 
umbilical vein endothelial cells. Moreover IS may be involved in the 
pathogenesis of atherosclerosis in CKD patients, because it promotes worsening 




cell proliferation [98]. Such in vitro experiments suggest that IS may play a role 
in the dysfunction of endothelial and vascular smooth muscle cells in CKD 
patients [87]. Gondouin and coworkers [99] reported the mechanism by which 
IS elicits this effect. IS is an agonist for the aryl hydrocarbon receptor (AhR) on 
vascular smooth muscle cells. The activation of this receptor inhibits the 
degradation of tissue factor, an initiator of coagulation, increasing its levels in 
endothelial cells.  
Adijiang and coworkers [100] have demonstrated that IS promotes aortic 
calcification and aortic wall thickening in hypertensive rats. They also have 
further demonstrated in vitro that IS stimulates the generation of free radicals 
such as superoxide by up-regulating NADPH oxidase, and induces the 
expressions of osteoblast-specific proteins in human aortic smooth muscle cells. 
Free radicals production is important in inducing the transdifferentiation of 
human aortic smooth muscle cells into cells with a more osteoblastic phenotype.  
Vascular calcification plays a vital role in the development of cardiovascular 
morbidity and its resultant increased mortality, while vascular calcification 
affects both vascular intima and media layers, its underlying mechanism 
remains poorly understood. Other studies found that in patients with 
cardiomyopathy and CKD Stage 1 to 3, higher total IS levels were associated 
with risk of hospitalization for heart failure and cardiac death. 
Barreto and coworkers [101] observed greater risk of cardiovascular mortality 
in CKD patients with increased total IS levels.  
It has recently been reported the osteoblast cytotoxicity of IS. It induces 
oxidative stress in osteoblasts, impair osteoblast function and down-regulates 
parathyroid hormone (PTH) receptor expression and consequently leasds to 
osteodystrophy such as low-turnover bone [102].  
Patients with renal failure exhibit neurological symptoms. Cognitive 
impairment is prominent and thought to be due to the accumulation of solutes 




CKD patients (30µM) compared to control subjects (4.7 µM) [103]. Limited 
studies have related uremic solutes levels to cognitive impairment and their 
results have been inconclusive. Among various uremic toxins, IS is a likely 
candidate renal triggered cerebraldysfunction [104]. Yeh and coworkers [105] 
found higher IS levels were associated with impaired executive function in 
patients with CKD stage 3. There was no association, however, in the patients 
with more advanced CKD. A recent metabolomic analysis in hemodialysis 

























































AIM OF THE WORK 
IS has been considered mainly as a nefro-toxin Considering that cognitive 
dysfunctions are frequent in CKD patients and it has been reported an IS 
accumulation, throught the OAT1/3 channels, in brain during CKD, in this 
project it has been examined the effects of IS on neuroinflammation and 
oxidative stress in CNS cells. For this purpose in vitro, in vivo and ex vivo 
experimental models have been used. 
This study will be a step towards elucidating whether if this toxin could be a 
potential pharmacological therapeutic targets or solely biomarkers of disease 

























































MATERIALS AND METHODS 
 
3.1 Reagents 
Unless stated otherwise, all reagents and compounds were purchased from 
Sigma Chemicals Company (Sigma, Milan, Italy). 
 
3.2 Cell cultures 
3.2.1 In vitro studies 
Glioma cells (C6) were obtained from American Type Culture Collection 
(ATCC; Manassas, VA, USA). Cells were grown in DMEM, 10% FBS (mL/L), 
2 mML-glutamine and penicillin/streptomycin (100 units/0.1 mg/mL) at 37 °C 
in 5% CO2 atmosphere. Cells were passaged at confluence using a solution of 
0.025% trypsin and 0.01% EDTA. The C6 glioma cell line was originally 
derived from rat brain tumors induced by N-nitrosomethylurea [107]; these cells 
have oligodendrocytic, astrocytic and neuronal properties [108] and are widely 
used as an astrocyte-like cell line [109]. 
 
3.2.2 Ex-vivo studies 
3.2.2.1 Primary astocytes and glial cells 
Mixed glial cell cultures from cortex and spinal cord were prepared from 
postnatal day 1–2 mouse pups (Female C57BL/6J mice; Harlan Laboratories, 
Udine, Italy). Mice were fed with standard chow diet and housed under specific 
pathogen-free conditions at the University of Messina, Department of Chemical, 
Biological, Pharmaceutical and Environmental Sciences. All animal 
experiments were performed under protocols that followed the Italian and 
European Community Council for Animal Care (DL. 26/2014). Cerebral 




hemispheres were transferred to Petri dishes containing HBSS and were cut into 
4 small pieces. Brains were centrifuged for 1 min at 200-300g. The supernatant 
was removed and the pellet was incubated with HBSS/10mM HEPES buffer, 
0.5 mg/ml Papain, 10μg DNAse solution for 25 min at 37°C. The extracted cells 
were centrifuged for 5 min at 200-300g and the pellet was resuspend in BME 
medium (10% FBS and 0.5% penicillin/streptomycin). The cell suspension was 
filtered through a 70-µm cell strainer to remove debris. The extracted cells were 
suspended in BME medium (10% FBS and 0.5% penicillin/streptomycin) in 75 
cm3 flasks. Medium was changed after 48 h and then twice per week [110]. 
After 20 days, in some flasks, microglia were dislodged using an orbital shaker 
(200 rpm for 1 h, 37°C). Moreover to remove residual microglia from the 
remaining cell monolayers, it was used a 60-min exposure (50 mM) to the 
lysosomotropic agent Leu-Leu-OMe (<5 % microglia, flow cytometry using 
anti-Iba1 as antibody) [111].  
 
3.2.2.2 Primary neurons 
Dissociated cell cultures of mouse cortex and hippocampus were established 
from day 16 C57BL/6J mouse embryos, as previously described [112]. Cortical 
and hippocampal neurons were plated in 35, 60 or 100-mm diameter 
polyethylenimine-coated plastic dishes and maintained at 37 °C in Neurobasal 
medium containing 25 mM of glucose and B-27 supplement (Invitrogen), 2 mM 
Lglutamine, 0.001% gentamycin sulfate and 1 mM HEPES (pH 7.2). 
Approximately 95% of the cells in such cultures were neurons and the remaining 
cells were astrocytes. 
 
3.2.3 Cell treatment 
C6 cells, primary astrocytes and mixed glial cell cultures were plated and 




medium and cells were treated with IS (15-60 µM) for 1h alone or in 
combination with LPS (1 µg/ml) and Interferon γ (IFN 100 U/ml) for 24h. 
Primary cortical and hippocampal neuronal cultures were plated and allowed to 
adhere for 2 weeks; thereafter, the medium was replaced with fresh medium and 
cells were treated with IS (15-60 µM) or with supernatant from primary 
astrocytes and mixed glial cultures treated with IS (15-60µM) for 24h. 
For the experiments, we referred to the list of uremic toxins provided by the 
European Uremic Toxin Work group [69] and thus consided an IS concentration 
range found in the cerebrospinal fluid of CKD patients [112]. 
 
3.3 Nitrite determination 
C6 cells were plated at a density of 3.0x105 cells/well into 24-well plates and 
primary astrocytes and mixed glial cell cultures were plated at a density of 
1.5x105 cells/well into 24-well plates. Thereafter, the medium was replaced with 
fresh medium and cells were treated with IS (15-60 µM) for 1 h and then co-
exposed to LPS (1 µg/ml)+IFN (100 U/ml). In some experiments with C6 cells, 
pyrrolidine dithiocarbamate (PDTC; 200 μM) a potent NF-kB inhibitor or CH-
223191 (1 μM), a selective AhR antagonist, were added 1 h before IS. NO 
generation was measured as nitrite (NO2
-), index of NO released by cells, in the 
culture medium 24 h after LPS stimulation by Griess reaction, as previously 
reported [113]. Briefly, 100 µL of cell culture medium were mixed with 100 µL 
of Griess reagent – equal volumes of 1% (w:v) sulphanilamide in 5% (v:v) 
phosphoric acid and 0.1% (w:v) naphtylethylenediamine-hydrogen chloride 
(HCl) and incubated at room temperature for 10 min, and then the absorbance 
was measured at 550 nm in a microplate reader Titertek (Dasit, Cornaredo, 
Milan, Italy). The amount of NO2
-, as µM concentration, in the samples was 
calculated by a sodium NO2





3.4 iNOS, COX-2, HO-1, NQO1, SOD, caspase-1 and nitrotyrosine 
detection  
iNOS, cicloxygenase-2 (COX-2), heme oxigenase-1 (HO-1), NAD(P)H 
dehydrogenase quinone 1 (NQO1), superoxide dismutase (SOD) expression and 
nitrotyrosine formation in C6 cells and iNOS, COX-2, HO-1 expression and 
nitrotyrosine formation were assessed by cytofluorimetric analysis primary 
astrocytes and mixed glial cell cultures. C6 cells were plated into 96-well plates 
(5×104 cells/well) and astrocytes and mixed glial cell cultures were plated into 
96-well plates (3.5×104 cells/well) and were allowed to grow for 24 h at 37 °C 
in a 5% CO2 atmosphere before experiments. Thereafter the medium was 
replaced with fresh medium and cells were treated with IS (15-60 µM) for 1 and 
then co-exposed to LPS (1 µg/ml)+IFN (100 U/ml) for further 24 h. Cells were 
collected, washed twice PBS and then incubated in Fixing Solution for 20 min 
at 4°C and then incubated in Fix Perm Solution for 30 min at 4°C. Anti-iNOS 
antibody, anti-COX-2 antibody (BD Laboratories), anti-HO-1 antibody (Santa 
Cruz Biotechnologies), anti-NQO1 antibody (Santa Cruz Biotechnologies), 
anti-SOD antibody (Santa Cruz Biotechnologies) and anti-nitrotyrosine 
antibody (Millipore) were then added to C6 cells for further 30 min and anti-
iNOS, anti-COX-2 (BD Laboratories), anti-nitrotyrosine antibody (Millipore) 
and HO-1 (Santa Cruz Biotechnologies) were added to astrocytes and mixed 
glial cells for further 30 min. The secondary antibody was added in Fix Perm 
solution and cells were evaluated using a fluorescence-activated cell sorting 
(FACSscan; Becton Dickinson) and elaborated with Cell Quest software as 
previously reported [114]. 
Caspase-1 protein expression in C6 cells was assessed by Western blot analysis. 
C6 cells were seeded in P60 plates (1.8x106 cells/P60) and allowed to adhere. 
Thereafter, the medium was replaced with fresh medium and cells were treated 
with IS (15-60 µM) for 1 h and then co-exposed to LPS (1 µg/ml)+IFN (100 




Cells were scraped off, washed with ice-cold phosphate-buffered saline (PBS), 
and centrifuged at 5.000 g for 10 min at 4°C. The cell pellet was lysed in a buffer 
containing 20 mM Tris HCl (pH 7.5), 1 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 mM sodium fluoride, 
150 mM sodium chloride, 10 mg/ml trypsin inhibitor, and 1% Tween-20. 
Protein concentration was estimated by the Bio-Rad protein assay using bovine 
serum albumin as standard. Equal amounts of protein (50 µg/line) were 
dissolved in Laemmli’s sample buffer, boiled, and run on a SDS polyacrylamide 
gel electrophoresis (SDS-PAGE) minigel (8% polyacrylamide) and then 
transferred to hybond polyvinylidene difluoride membrane for 40 min. at 5 mA 
cm2 into 0.45 mm. Membranes were blocked for 40 min in PBS and 5% (w/v) 
nonfat milk and subsequently probed overnight at 4°C with mouse monoclonal 
anti-caspase-1 (Abcam) in PBS, 5% w/v non fat milk, and 0.1% Tween-20. 
Blots were then incubated with horseradish peroxidase conjugated goat 
antimouse immunoglobulin (Ig)G (1:5.000) for 1 h at room temperature. 
Immunoreactive bands were visualized using electro-chemiluminescence assay 
(ECL) detection system according to the manufacturer’s instructions and 
exposed to Kodak X-Omat film. The protein bands of caspase-1 and tubulin on 
XOmat films were quantified by scanning densitometry (Imaging Densitometer 
GS-700 BIO-RAD U.S.A.). Data were normalized with tubulin expression, used 
as reference protein, and expressed as arbitrary densitometric units as previously 
reported [114]. 
 
3.5 TNF-α, IL-6 and IL-1β determination 
TNF-α, IL-6 and IL-1 β concentration in the supernatant of C6 cells and cultured 
primary astrocytes and mixed glial cells stimulated for 1h with IS (15-60 µM) 
and then co-exposed to LPS (1 µg/ml)+IFN (100 U/ml) for further 24 h were 
assessed by an Enzyme-Linked Immuno Sorbent Assay (ELISA) assay. In some 




1 h before IS. For this we used commercially available kits for murine TNF-α 
and IL-6 according to manufacturer’s instruction (e-Biosciences, CA, USA).  
 
3.6 Immunofluorescence analysis with confocal microscopy 
For immunofluorescence assay, C6 cells (3.0x105/well), primary astrocytes and 
mixed glial cells (2.0x105/well) were seeded on coverslips in 12 well plate and 
treated for 1 h with IS (30 µM) and then co-exposed to LPS (1 µg/ml)+IFN (100 
U/ml) for 1h. In some experiments with C6 cells, PDTC (200 μM) or CH-
223191 (1 μM), were added 1 h before IS. 
Then cells were fixed with 4% paraformaldehyde in PBS and permeabilized 
with 0.1% Triton X-100 in PBS. After blocking with BSA and PBS, cells were 
incubated with rabbit anti-nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
antibody (Santa Cruz Biotechnologies), with mouse anti-AhR antibody 
(Abcam) and with rabbit anti-p65 NF-kB antibody (Santa Cruz 
Biotechnologies) for 1 h at 37°C. The slides were then washed with PBS for 
three times and fluorescein-conjugated secondary antibody was added for 1 h. 
DAPI was used for counterstaining of nuclei. Coverslips were finally mounted 
in mounting medium and fluorescence images were taken using the Laser 
Confocal Microscope (Leica TCS SP5). 
 
3.7 Measurement of ROS 
ROS formation was evaluated utilizing the probe 2’,7’-dichlorofluorescin-
diacetate (H2DCF-DA) as previously reported [116]. In the presence of 
intracellular ROS, H2DCF is rapidly oxidized to the highly fluorescent 2’,7’-
dichlorofluorescein (DCF). Briefly, C6 cells were plated at a density of 3.0x105 
cells/well into 24-well plates and primary astrocytes and mixed glial cell 
cultures were plated at a density of 1.5x105 cells/well into 24-well plates. Cells 
were allowed to adhere for 24h; thereafter, the medium was replaced with fresh 




to LPS (1 µg/ml)+IFN (100 U/ml) for 24 h. Cells were then collected, washed 
twice with PBS buffer and incubated in PBS containing H2DCF-DA (10 µM) 
at 37°C. After 45 minutes, cellular fluorescence was evaluated using 
fluorescence-activated cell sorting analysis (FACSscan; Becton Dickinson) and 
elaborated with Cell Quest software. In some experiments, in C6 cells, either 
Diphenyliodonium (DPI; 10 µM), that has frequently been used to inhibit ROS 
production mediated by flavoenzymes, and N-acetylcysteine (NAC; 20 mM), 
an effective scavenger of free radicals as well as a major contributor to 
maintenance of the cellular glutathione status, were added 1 h before IS.  
 
3.8 Wound-healing Assay 
C6 cells were seeded in a 12-well plastic plate at (3.0x105/well) and allowed to 
adhere for 24 h. Then a wound was produced at the centre of the monolayer by 
gently scraping cells with a sterile plastic p200 pipette tip. Then the incubation 
medium was removed and cells washed with PBS and incubated with IS (15-60 
µM) for 1 h and then co-exposed to LPS (1 µg/ml)+IFN (100 U/ml) for 24h. In 
some experiments DPI (10 µM) was added 1 h before IS. The wounded cell 
cultures were then incubated at 37°C in a humidified and equilibrated (5% v/v 
CO2) incubation chamber of an Integrated Live Cell Workstation Leica AF-
6000 LX. A 10x phase contrast objective was used to record cell movements 
with a frequency of acquisition of 10 min. The migration rate of individual cells 
was determined by measuring the distances covered from the initial time to the 
selected time-points (bar of distance tool, Leica ASF software). For each 
condition three independent experiments were performed. For each wound three 
different positions were registered, and for each position ten different cells were 
randomly selected to measure the migration distances. Statistical analyses were 






3.9 Antiproliferative activity 
C6 cells (5x104/well) and astrocytes and mixed glial cell cultures (3.5x104/well) 
were plated on 96-well plates and allowed to adhere for 24 h. Thereafter, the 
medium was replaced with fresh medium alone or containing serial dilutions of 
IS (15-60 µM) and incubation was performed for 24 h. Cell viability was 
assessed using the MTT assay as previously reported [117]. Briefly, 25 µL of 
MTT (5 mg/mL) were added and cells were incubated for an additional 3 h. 
Thereafter, cells were lysed and the dark blue crystals solubilised with 100 µL 
of a solution containing 50% (v:v), Ndimethylformamide, 20% (w:v) SDS with 
an adjusted pH of 4.5. The optical density (OD) of each well was measured with 
a microplate spectrophotometer (Titertek Multiskan MCC/ 340-DASIT) 
equipped with a 620 nm filter. C6 cells viability in response to treatment with 
IS, was calculated as: % dead cells = 100x[(OD treated/OD control) x100]. 
 
3.10 Analysis of Apoptosis and Cell Cycle Distribution 
Hypodiploid DNA was analyzed using propidium iodide (PI) staining by flow 
cytometry [116]. Briefly, 3.0x105 C6 cells and 1.5x105 astrocytes and mixed 
glial cell cultures were grown in 24-well plates and allowed to adhere. Cells 
were allowed to grow for 24 h; thereafter, the medium was replaced with fresh 
medium and cells were stimulated with IS (15-60 µM) for 24 h. In some 
experiments in C6 cells, DPI (10 µM) or NAC (20 mM) were added 1 h before 
IS. Following treatment, culture medium was removed, cells washed once with 
PBS and then resuspended in 500 µL of a solution containing 0.1% (w/v) 
sodium citrate, 0.1% Triton X-100 and 50 µg/mL propidium iodide (PI). Culture 
medium and PBS were centrifuged and cell pellets were pooled with cell 
suspension to retain both dead and living cells for analysis. After incubation at 
4°C for 30 min in the dark, cell nuclei were analyzed with a Becton Dickinson 
FACScan flow cytometer using the CellQuest program and the DNA content of 




from the analysis by raising the forward scatter threshold, then the percentage 
of cells in the hypodiploid region (sub G0/G1) was calculated. Data are 
expressed as the percentage of cells in the hypodiploid region. For cell cycle 
analysis samples were analysed with a FACScan flow cytometer (Becton 
Dickinson, CA) using Mod FitLT program. 
 
3.11 Cytotoxicity assay on primary cortical and hippocampal neuronal 
cultures 
The cytotoxicity assay was performed using the Cytotoxicity Detection 
KitPLUS LDH (Roche) according to the manufacturer’s instructions. This assay 
is based on the measurement of lactate dehydrogenase (LDH) activity released 
from the cytosol of damaged cell. Cell cytotoxicity was studied by LDH activity 
on primary cortical neuronal cultures treated with IS (15-60µM), for 3 h. Three 
controls are included: background control (assay medium), low control 
(untreated cells) and high control (maximum LDH release). To determine the 
experimental absorbance values, the average absorbance values of the triplicate 
samples and controls were calculated and subtracted from the absorbance values 
of the background control. The percent cytotoxicity was determined using the 
following equation: Cytotoxicity (%) = (exp. value − low control)/(high control 
− low control) × 100. 
 
3.12 In vivo studies 
Female C57BL/6J mice (6–8 weeks; Harlan Laboratories, Udine, Italy) were 
fed a standard chow diet and housed under specific pathogen-free conditions at 
the University of Messina Animal Care Review Board approved the study. All 
animal experiments were performed following the regulations in Italy (D.M. 
116192), Europe (O.J. of E.C. L 358/1 12/18/1986), USA (Animal Welfare 




IS was dissolved in PBS and it was injected into mice (800 mg/kg, i.p. given 
once). After 3h of treatment, animals were sacrified and kidneys, brains and 
serum were collected and stored at -80° for the analysis [118].  
 
3.13 IS serum evaluation by HPLC  
IS levels in mice serum were evaluated according the methods of Zhu and 
coworkrset [119] as previously reported [120].  
 
3.14 Serum nitrite/nitrate, TNF-α and IL-6 evaluation  
Nitrite/nitrate, TNF-α, IL-6 content was evaluated on serum samples of mice 
treated with IS (800 mg/kg) for 3h. Plasma nitrite/nitrate (NOx) concentration 
is a marker of NO generation. For its measurement, plasma samples were 
incubated with nitrate reductase (0.1 U/mL), NADPH (1 mm) and FAD (50 
µm). After 15 minutes, samples were incubated with LDH (100 U/mL) and 
sodium pyruvate (10 mm) for 5 minutes. The total NOx concentration was 
measured by the Griess reaction after adding 100 µL of Griess reagent (0.1% 
naphthylethylenediamide dihydrochloride in H2O and 1% sulfanilamide in 5% 
conc. H2PO4; vol. 1 : 1) to 100 µL of samples, each in triplicate. The optical 
density at 550 nm (OD550) was measured at 540 nm in a microplate reader 
Titertek (Dasit, Cornaredo, Milan, Italy). Total NOx concentrations (µM) were 
calculated from a standard curve of sodium nitrate. NO generation was 
measured as NO2
-, index of NO released in serum by Griess reaction, as 
previously reported [121]. Briefly, 100 µL of cell culture medium were mixed 
with 100 µL of Griess reagent – equal volumes of 1% (w:v) sulphanilamide in 
5% (v:v) phosphoric acid and 0.1% (w:v) naphtylethylenediamine-hydrogen 
chloride and incubated at room temperature for 10 min, and then the absorbance 
was measured at 550 nm in a microplate reader Titertek (Dasit, Cornaredo, 
Milan, Italy). The amount of NO2
- as µM concentration, in the samples was 
calculated by a sodium NO2




TNF-α and IL-6 concentration in serum mice was assessed by an Enzyme-
Linked Immuno Sorbent Assay (ELISA;e-Biosciences, CA, USA).  
 
3.15 Histology and immunohistochemistry 
For the histological examination, kidney and brain from sacrificed mice were 
immediately incised and fixed in 10% formalin. Paraffin-embedded 4 µm 
sections were stained with haematoxylin and eosin (H&E) for morphological 
evaluation. 
For immunohistochemistry analysis, 4-µm-thick sections of the brain and 
kidney tissue were collected on silane-coated glass slides (Bio-Optica, Milan). 
Immunohistochemical stain was performed using horseradish peroxidase (HRP) 
conjugated antibodies. Antigen retrieval pretreatments were performed using a 
HIER citrate buffer pH 6.0 (Bio-Optica, Milan, Italy) for 20 minutes at 98 °C. 
Endogenous peroxidase (EP) activity was quenched with 3% hydrogen peroxide 
(H2O2) in methanol and sections were treated with a blocking solution 
(MACH1, Biocare Medical LLC, Concord, California, USA) for 30 minutes 
each. Slides were sequentially incubated overnight at 4°C with primary antibody 
diluted in PBS (0.01 M PBS, pH 7,2).  
The primary antibodies used were: a mouse anti-COX-2 (BD Transduction 
Laboratories used at dilution 1:250; a rabbit anti-nitrotyrosine purchased from 
Millipore (Temecula, CA; used at dilution 1:100). 
Antigen-antibody binding was detected by a horseradish-peroxidase (HRP) 
polymer detection kit (MACH1, Biocare Medical LLC, Concord, California, 
USA). Antibody deposition was visualized using the DAB chromogen diluted 
in DAB substrate buffer and the slides were counterstained with haematoxylin. 
Between all incubation steps, slides were washed two times (5 minutes each) in 
PBS. For each tissue section, a negative control was performed using an 





3.16 ROS production from C6 cells treated with CKD serum patients 
In preliminary experiments we evaluated the effect on ROS release from C6 
cells, as reported in paragraph 3.7, treated with serum from six subjects: two 
healthy and four CKD patients (kindly provided by Dr. B.R. Di Iorio Ospedale 
“A. Landolfi”-Solofra- AV). In another set of experiments, before ROS 
evaluation from C6 cells, serum patients were incubated with 1 g/dl AST-120 
for 3 h at 37°C and the supernatants were filtered. AST-120 is an oral intestinal 
spherical carbon adsorbent consisting of porous carbon particles that are 0.2–
0.4 mm in diameter and insoluble in water and common organic solvents. It is 
an orally administered intestinal sorbent, adsorbs IS, thereby reducing serum 
and urinary concentrations of IS [122]. 
 
3.17 Data analysis 
Data are presented as standard error of the mean (s.e.m.) showing the combined 
data of at least three independent experiments each in triplicate. Statistical 
analysis was performed by analysis of variance test, and multiple comparisons 




















4.1 IS enhanced NO release, iNOS and COX-2 expression and TNF-α 
production in C6 cells 
In order to evaluate the effect of IS on NO production, we measured NO2 release 
in cellular medium of C6 cells. A marked increase of NO2 production in cellular 
medium was observed at 24 h after LPS + IFN stimulation (P<0.001 vs control; 
Figure 4.1 A). When IS (15-60 µM), added to C6 cells 1 h before and together 
with LPS+IFN for 24 h, a significant and concentration-dependent increase of 
NO2 production in cell medium was observed (P<0.001; Figure 4.1 A). Under 
the same experimental conditions we also observed a significant induction in 
iNOS and COX-2 expression in C6 cells treated with LPS+IFN (P<0.001 vs 
control; Figure 4.1 B,C) and IS induced a significant and concentration-
dependent increase in iNOS and COX-2 expression (P<0.05 vs LPS+IFN; 
Figure 4.1 B,C). LPS+IFN induced a significant induction in TNF-α in C6 cells 
(P<0.001 vs control; Figure 4.1 D). This release was significantly enhanced by 
IS (15-60 µM) at all tested concentrations (P<0.01 vs LPS +IFN; Figure 4.1 D). 
No increase in NO release and in iNOS and COX-2 expression and TNF-α 





















































































Figure 4.1 A,B: Effect of IS on NO production (A), on iNOS (B) expression. 


























































































Figure 4.1 C,D: Effect of IS on COX-2 expression (C) and on TNF-α release 
(D). °°° denotes P<0.001 vs control. ***, ** and * denote P<0.001, P<0.01 




4.2 IS facilitated NF-kB p65 nuclear translocation induced by LPS+IFN in 
C6 cells 
After p65 NF-kB phosphorylation, the free NF-kB dimers translocate into the 
nucleus and bind to specific sequences to regulate downstream genes expression 
[123]. Thus we labelled p65 with green fluorescence to track the influence of IS 
(30 µM), on NF-kB translocation. As shown in figure 4.2 A, nuclear p65 was 
increased after IS. NF-kB translocation is further enhanced by IS in C6 cells 
when compared to LPS+IFN alone (Figure 4.2 A). To evaluate the possible 
involvement of NF-kB in NO and TNF-α release induced by IS, we analyzed 
these mediators production in presence of PDTC. In this experimental condition, 
PDTC reduced significantly NO and TNF-α production (P<0.001 vs 

























Figure 4.2 A: Effect of IS (30 μM) on p65 nuclear translocation in C6 cells. 
Nuclear translocation of NF-kB p65 subunit was detected using 
immunofluorescence assay at confocal microscopy. Scale bar, 10µm. Blue and 
green fluorescences indicate localization of nucleus (DAPI) and p65 







































































































































































































Figure 4.2 B,C: Effect of IS (15-60 μM) on NO (Panel B), TNF-α (Panel C) 
production in C6 cells in presence of PDTC. °°° denotes P<0.001 vs control. 
***, ** and * denote P<0.001, P<0.01 and P<0.05 vs LPS+IFN. òòò denotes 






4.3 IS interfered with inflammatory response through AhR in C6 cells 
AhR is a nuclear transcription factor involved in multiple processes such as the 
xenobiotics metabolism and inflammatory process. Recent studies have shown 
that the IS is an agonist of the AhR receptor [124]. Therefore, we investigated 
AhR through green fluorescent labelling under normal conditions, in the 
presence of IS (30 µM) and LPS+IFN. After 1 h nuclear presence of AhR was 
icreased after IS treatment and the IS effect was enhanced in inflammatory 
conditions (Figure 4.3 A). To evaluate the possible involvement of AhR in NO 
and TNF-α release induced by IS, we analyzed these mediators production in 
presence of the AhR inhibitor: CH-223191. CH-223191 significantly reduced 
IS induced NO and TNF-α production (P<0.001 vs IS; Figure 4.3 B,C). In order 
to evaluate the interaction between AhR and NF-kB in our experimental 
conditions, we assesed if the addion of PDTC might interfere with the activation 
of AhR and if the addition of CH-223191 could affect p65 NF-kB nuclear 
translocation, induced by IS in presence of LPS + IFN. As shown in figure 4.4 
(A,B), AhR nuclear translocation was inhibited by PDTC and also NF-kB 
nuclear translocation was inhibited by CH-223191 in both normal and in 




































Figure 4.3 A: Effect of IS (30 μM) on AhR nuclear translocation in C6 cells. 
Nuclear translocation of AhR was detected using immunofluorescence assay at 
confocal microscopy. Scale bar, 10µm. Blue and green fluorescences indicate 
localization of nucleus (DAPI) and AhR respectively. Analysis was performed 


























































































































































































































Figure 4.3 B,C: Effect of IS (15-60 μM) on NO (Panel B), TNF-α (Panel C) 
production in C6 cells in presence of CH-223191. °°° denotes P<0.001 vs 
control. *** and * denote P<0.001 and P<0.05 vs LPS+IFN. ### and ## 









Figure 4.4 A: Effect of IS (30 μM) on AhR activation in presence of PDTC in 
C6 cells. Nuclear translocation of AhR was detected using 
immunofluorescence assay at confocal microscopy. Scale bar, 10µm. Blue and 
green fluorescences indicate localization of nucleus (DAPI) and AhR 




















Figure 4.4 B: Effect of IS (30 μM) on NF-kB nuclear translocation in 
presence of CH-223191 in C6 cells. Nuclear translocation of NF-kB was 
detected using immunofluorescence assay at confocal microscopy. Scale bar, 
10µm. Blue and green fluorescences indicate localization of nucleus (DAPI) 
















4.4 IS induced inflammasome activation in C6 cells 
IS induced inflammasome activation by an increase of caspase-1 expression and 
IL-1β production in C6 cells (Figure 4.5). We observed that IS (15-60 µM) 
added 1h before and simultaneously with LPS + IFN for 24h, increased caspase-
1 expression in C6, in inflammatory conditions (P<0.001 vs control and P<0.01 
vs LPS + IFN; Figure 4.5 A). In the same experimental conditions IS (15-60 
µM) significant increased IL-1β levels (P<0.01 vs control and P<0.05 vs 






















































Figure 4.5: Effect of IS on caspase-1 expression (A)and on IL-1β release (B). 
°°° and °°denote P<0.001 and P<0.01 vs control. ***, ** and * denote 




4.5 IS enhanced ROS release in C6 cells 
In order to investigate the effect of IS on oxidative stress in C6 cells, we 
evaluated intracellular ROS production. Our results showed that IS in all tested 
concentrations (15-60 µM), induced a significant dose dependent increase in 
ROS production (P<0.001 vs control; Figure 4.6 A). We examined ROS 
production also in presence of DPI (10 µM) and NAC (20 mM), to deep insight 
the mechanisms of IS-induced ROS in C6 cells. As shown in figure 4.6A, DPI 
and NAC significantly inhibited ROS release induced by IS (P<0.001 vs IS, 
Figure 4.6 A). A more marked effect was observed when IS was added 1h before 
and simultaneously with LPS+IFN for 24h. In this experimental conditions IS 
strongly increased ROS release (P<0.001 vs LPS+IFN; Figure 4.6 B) and the 
presence of DPI and NAC reduced IS-induced ROS in inflammatory conditions 
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Figure 4.6: Effect of IS on ROS production in normal (A) and in inflammatory 
conditions (B) in presence of DPI and NAC, in C6 cells. °°° denotes P<0001 
vs control. òòò denotes P<0.001 vs IS. *** denotes P<0.001 vs LPS+IFN. ### 





4.6 IS reduced Nrf2 nuclear translocation and HO-1, NQO1 and SOD 
expression in C6 cells 
Following its activation, Nrf2 translocates into the nucleus and regulates cell 
protective gene expression. We labelled Nrf2 with a green fluorescence to track 
the influence of IS (30 µM) added for 1 h. In presence of IS, we observed a 
reduction in Nrf2 nuclear translocation (Figure 4.7 A). This reduction was more 
evident when C6 cells were stimulated with IS in presence of LPS+IFN (Figure 
4.7 A). 
Enzymes dealing with oxygen radicals are in order to induce an anti-oxidant 
response HO-1, NQO1 and SOD. In oder to assess their expression profile in 
the presence of IS, we treated C6 cells with IS (15-60 µM). After 24 h, we 
observed that IS alone induced a decrease in HO-1 expression (P<0.05 vs 
control for HO-1; Figure 4.7 B). A weak but not significant inhibition was 
observed on NQO1 and SOD expression (Figure 4.7 C,D). When IS (15-60 µM) 
was added for 1h and then simultaneously with LPS+IFN for 24h, a further 
decrease of HO-1, NQO1 and SOD expression in C6 cells was observed (P<0.05 




















Figure 4.7A: Effect of IS (30 μM) on Nrf2 nuclear translocation in C6 cells. 
Nuclear translocation of Nrf2 was detected using immunofluorescence assay 
at confocal microscopy. Scale bar, 10µm. Blue and green fluorescences 
indicate localization of nucleus (DAPI) and Nrf2 respectively. Analysis was 


















































































Figure 4.7 B,C: Effect of IS (15-60 μM) on HO-1 (Panel B) and NQO1 (Panel 
C) expression in C6 cells in normal and in inflammatory conditions. °°°, °° 
and ° denote P<0.001, P<0.01 and P<0.05 vs control. ***,** and * denote 












































Figure 4.7 D: Effect of IS (15-60 μM) on SOD expression in C6 cells in 
normal and in inflammatory conditions. °°° denotes P<0.001 vs control. ** 



















4.7 IS enhanced nitrotyrosine formation in C6 cells 
In order to assess whether the IS influenced nitrotyrosine formation, we treated 
C6 cells with IS (15-60 µM) for 1h and then co-exposed with LPS+IFN for 24 
h. When IS (15-60 µM) was added to astrocytes in our experimental conditions, 
an increase of nitrotyrosine formation was observed compared to C6 cells 

























































Figure 4.8: Effect of IS on nitrotyrosine formation. °°° denotes P<0.001 vs 











4.8 Effect of IS on C6 cell migration: effect of DPI 
The ability of astrocytes to migrate and then to discharge mechanisms of 
neuronal repair, after IS treatment was assessed by wound healing assay in the 
presence of IS (15-60 µM) in both normal and in inflammatory conditions. As 
shown in figure 4.9, IS (15-60 µM) treatment induced a reduction cell migration 
rate compared to untreated cells (P<0.01 vs control; Figure 4.9). When IS was 
added 1h before and simultanously with LPS+IFN, a weak and significant 
inhibition was observed in cell migration rate (P<0.01 vs LPS+IFN, Figure 
4.9A). To study the mechanisms of IS-induced a reduction of cell migration, we 
examined astrocytes migration after treatment with IS (15-60 µM), in the 
presence of DPI. As shown in figure 4.9 B, DPI significantly increased cell 
migration in both normal and in inflammatory conditions (P<0.01 vs IS, P<0.05 
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Figure 4.9 A: Representative pictures of wound repair from mechanical 
scratch 24 h after IS (15-60 μM). Quantitative analysis of the wound repair 24 
h after making the scratch. °°° and °° denote P<0.001 and P<0.01 vs control. 











































Figure 4.9 B: Representative pictures of wound repair from mechanical 
scratch 24 h after IS (15-60 μM) in presence DPI cells treatment. Quantitative 
analysis of the wound repair 24 h after making the scratch. ò denotes P<0.001 




4.9 IS affected cells viability, induced apoptosis and cell cycle arrest in C6 
cells 
To elucidate the influence of IS on C6 cells viability under our experimental 
conditions, cells were treated with IS (15-60 µM) for 24 h. Our data indicated 
that IS affected astrocytes viability mostly at the highest concentration (60 µM, 
P<0.01 vs control; Figure 4.10 A). 
In order to investigate the mechanism(s) underlying cell observed decrease in 
cell viability observed in IS treated C6 cells a cytofluorimetric analysis was 
performed by incubating C6 with IS (15-60 µM) for 24 h. Apoptosis was 
evaluated by cytofluorimetric analysis of PI stained hypodiploid nuclei (Figure 
4.10 B). In another series of experiment C6 cells were treated with DPI, a 
NAD(P)H oxidase inhibitor, in order to evaluated the potential role of the pro-
oxidative enzymes NAD(P)H oxidase in the apoptosis induced by IS, or with 
NAC, an antioxidants. Our results indicated that IS (30-60 µM) significantly 
induced apoptosis in C6, in a concentration-dependent manner (P<0.01 vs 
control; Figure 4.10 B). The addition of DPI (P<0.01 vs IS; Figure 4.10 B) and 
NAC (P<0.05 vs IS; Figure 4.10 B) reduced significantly the apoptotic process 
induced by IS. 
In order to determine if IS could also affect cell cycle distribution we carried 
out a cell cycle analysis. C6 cells were treated with IS (15-60 µM) for 24 h. As 
showed in figure 10C, exposure to IS (60 µM) resulted in a significant increase 
of the G0/G1 (P<0.05 vs control) and S phase cell cycle distribution 
accompanied by a significant decrease in G2 phase (P<0.05 vs control) 










































































Figure 4.10 A,B: Effect of IS (15-60 μM) on C6 cell viability, evaluated at 24h 
(Panel A). Effect of IS (15-60 μM) on C6 cell apoptosis in presence of DPI 
(Panel B). °°° and °° denote P<0.001 and P<0.01 vs control. òò and ò denote 











































Figure 4.10 C: Effect of IS (15-60 μM) on cell cycle distribution of C6 cells. 
+++ and + denote P>0.001 and P<0.05 vs control (S fase). Ò denotes 
















4.10 IS enhanced NO release, iNOS and COX-2 expression and TNF-α and 
IL-6 production from primary astrocytes and mixed glial cell cultures 
IS significaltly and in aconcentration-related manner inhibited NO release in 
primary astrocytes, but mostly in mixed glial cell cultures and in inflammatory 
conditions (P<0.001 vs LPS+IFN; Figure 4.11 A). 
Under the same experimental conditions we also observed a significant 
induction in iNOS and COX-2 expression in astrocytes and mixed glial cell 
cultures treated with IS alone (15-60 µM; P<0.05 vs control) and further in 
inflammatory conditions (P<0.05 vs LPS+IFN, P<0.001 vs astrocytes; Figure 
4.11 B,C). 
IS treatment also induces a significant induction of TNF-α and IL-6 levels in 
astrocytes and mixed glial cell cultures (P<0.001 vs control and P<0.001 vs 
astrocytes alone; Figure 4.11 D,E). In particular this effect is more evident in 
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Figure 4.11 A,B: Effect of IS on NO production (A) and on iNOS (B) 
expression. °°° and ° denote P<0.001 and P<0.05 vs control. ***, ** denote 
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Figure 4.11 C,D: Effect of IS on COX-2 expression (C) and on TNF-α (D) 
release. °°° and ° denote P<0.001 and P<0.05 vs control. ***, ** and * 
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Figure 4.11 E: Effect of IS on and IL-6 release. °°° denotes P<0.001 vs 


















4.11 IS activated AhR and facilitated p65-NF-kB nuclear translocation in 
primary astrocytes and mixed glial cell cultures  
In these experiments AhR was labeled with green fluorescent to examine the 
influence of the IS (30 µM), added for 1 hour on its nuclear translocation. As 
shown in figure 4.12, AhR translocation was increased by IS in astrocytes and 
mixed glial cell cultures expecialy in inflammatory conditions. 
Moreover we labelled NF-kB p65 subunitwith a green fluorescence to track the 
influence of IS (30 µM), added for 1 h on NF-kB nuclear translocation. As 
shown in Figure 4.13, the presence of IS induced an enhancement of NF-kB 






Figure 4.12: Effect of IS (30 μM) on AhR activation in primary astrocytes and 
mixed glial cell cultures. Nuclear translocation of AhR was detected using 
immunofluorescence assay at confocal microscopy. Scale bar, 10µm. Blue and 







Figure 4.13: Effect of IS (30 μM) on NF-kB activation in primary astrocytes 
and mixed glial cell cultures. Nuclear translocation of NF-kB was detected 
using immunofluorescence assay at confocal microscopy. Scale bar, 10µm. 





4.12 IS enhanced ROS release from primary astrocytes and mixed glial cell 
cultures 
In order to investigate if IS induces oxidative stress in primary astrocytes and 
mixed glial cell cultures, we evaluated its effect on intracellular ROS 
production. Our results showed that IS, at all tested concentrations (15-60 µM), 
induced a significant ROS production in primary astrocytes and mixed glial cell 
cultures in bot normal and mostly in inflammatory conditions (P<0.01 vs 
control, P<0.01 vs LPS+IFN, P<0.001 vs astrocytes alone; Figure 4.14). In 
particular this effect was more evident in primary mixed glial cell cultures 
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Figure 4.14: Effect of IS on ROS production in primary astrocytes and mixed 
glial cell cultures. °°°, °° denote P<0.001, P<0.01 vs control. *** and ** 





4.13 IS enhanced nitrotyrosine formation in primary astrocytes and mixed 
glial cell cultures 
In order to evaluate the effectof IS on nitrotyrosine formation, astrocytes and 
mixed glial cell cultures were treated with IS (15-60 µM) for 1h and then 
simultaneously with LPS+IFN for 24h. When IS (15-60 µM) was added to 
astrocytes for 24 h, an increase of nitrotyrosine expression was observed 
(P<0.01 vs control; Figure 4.15). This effects resulted further increasead in 
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Figure 4.15: Effect of IS on nitrotyrosine formation in primary astrocytes and 
mixed glial cell cultures. °°°, °° denote P<0.001, P<0.01 vs control. *** and 








4.14 IS reduced Nrf2 nuclear translocation and HO-1 expression in 
primary astrocytes and mixed glial cell cultures  
As shown in figure 4.16 A, Nrf2 nuclear translocation was evident in the cell 
control. The presence of IS led a reduction of Nrf2 translocation respect to the 
control in both normal and in inflammatory conditions (Figure 4.16 A). 
Moreover in the same experimental conditions, IS induced also a reduction in 
HO-1 expression (P<0.05 vs control; Figure 4.16 B). In particular this effect 
was more evident in inflammatory conditions (P<0.01 vs LPS+IFN; Figure 4.16 
B). In primary mixed glial cell cultures the response was much more prominent 
respect the primary atrocytes, indicating the contribution of the microglial cells 























Figure 4.16 A: Effect of IS (30 μM) on Nrf2 nuclear translocation in primary 
astrocytes and mixed glial cell cultures (Panel A). Nuclear translocation of 
Nrf2 was detected using immunofluorescence assay at confocal microscopy. 
Scale bar, 10µm. Blue and green fluorescences indicate localization of 
nucleus (DAPI) and Nrf2 respectively. Analysis was performed by confocal 
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Figure 4.16 B: Effect of IS (15-60 μM) on HO-1 (Panel B) expression in 
primary astrocytes and mixed glial cell cultures in normal and in 
inflammatory conditions. °°°, °° and ° denote P<0.001, P<0.01 and P<0.05 vs 
















4.15 IS affected cell cultures viability induced apoptosis and cell cycle arrest 
in primary astrocytes and mixed glial cell cultures 
To elucidate the influence of IS on astrocytes and mixed glial cell cultures 
viability, we treated cells with IS (15-60 µM) for 24 h. Our results indicated that 
viability of astrocytes and glial cells was affected by IS treatment, especially to 
the concentration 30-60 µM (P<0.05 vs control and P<0.05 vs astrocytes alone; 
Figure 4.17A). In particular this effect is more evident in primary mixed glial 
cell cultures respect to primary astrocytes alone. 
In order to investigate the mechanism(s) underlying cell observed decrease in 
cell viability observed in IS treated astrocytes and mixed glial cell cultures, a 
cytofluorimetric analysis was performed by incubating cells with IS (15-60 µM) 
for 24 h. Our results indicated that IS significantly induced apoptosis in 
astrocytes and mixed glial cell cultures, in a concentration-dependent manner 
(P<0.05 vs control and P<0.05 vs astrocytes alone; Figure 4.17B).  
In order to determine if IS could also affect cell cycle distribution we carried 
out a cell cycle analysis. As showed in figure 4.17C, exposure to IS resulted in 
an increase of the G0/G1 (P<0.01 vs control) and S phase cell cycle distribution 
accompanied by a significant decrease in G2 phase (P<0.001 vs control) 
compared to untreated cells. In particular this effect is more evident in primary 
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Figure 4.17 A,B: Effect of IS (15-60 μM) on astrocytes and mixed glial cells 
viability, evaluated at 24h (Panel A). Effect of IS (15-60 μM) on astrocytes and 
mixed glial cells (Panel B). °°°, °° and ° denote P<0.001, P<0.01 and P<0.05 
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Figure 4.17 C: Effect of IS (15-60 μM) on cell cycle distribution of astrocytes 
and mixed glial cells. +++ and ++ denote P>0.001 and P<0.01 vs control (S 
fase).ççç,çç and ç denote P<0.001, P<0.01 and P<0.05 vs control (G1/G0 












4.16 IS increased cellular death in neuronal cultures 
In order to investigate the effect of IS on neuronal death we used primary 
cortical and hippocampal neuron cultures. Our results showed that both cortical 
and hippocampal neurons are susceptible to IS-induced neuronal cell death in a 
dose-dependent fashion (P<0.05 vs control, P<0.05 vs cortical neurons; Figure 
4.18 A). In another set of experiments, primary neurons were stimulated with 
the cells supernatant derived from IS-treated microglia. As showed in figure 
4.18 B, in this experimental condition, we observed an increase in cellular 
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Figure 4.18A: Effect of IS (15-60 μM) on cortical and on hippocampal 
neuronal cell viability. °°° and ° denote P<0.001 and P<0.05 vs control. # 
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Figure 4.18 B: Effect of supernatant from IS-treated microglia on cortical and 
on hippocampal neuronal cell viability (panel B). °°°, °° denote P<0.001, 






















4.17 IS induced brain and kidney damage 
According to previous observations [118], we found atrophic glomeruli with 
thickening of the Bowman's capsule and mesangial matrix and aspects of 
segmental solidification after IS treatment (Figure 4.19). The tubular epithelial 
cells showed granule-fatty degeneration and sometimes vacuoles and were 
arranged around amorphous and hypereosinophilic protein aggregates ("casts”; 
Figure 4.19). We observed interstitial edema, dilatation of renal arterioles and 
small hemorrhagic areas (Figure 4.19). We also observed IS effects in the brain. 
Histological evaluation showed some neurons showing cytoplasm angular 
margins, with eosinophilic cytoplasm and pyknotic nuclei (neuronal necrosis). 
Around the necrotic neurons were slightly hyperplastic glial cells (satellitosis). 
 
4.18 IS enhanced NO, TNF-α and IL-6 levels in mice serum and resulted in 
COX-2 and nitrotyrosine expression in brain and kidney 
To match our in vitro findings with the in vivo IS accumulation, we injected 
mice with IS (800 mg/Kg) which resulted in a significantly high IS serum 
concentration (79.66±1.67 µM vs 0.55±0.00 µM, P<0.001 vs control). Total 
nitrite serum increased significantly in IS-treated mice compared to control mice 
(89.76±9.98 vs 55.99±9.69 µM, P<0.05). TNF-α and IL-6 serum levels were 
upregulated 18.91±1.77 vs 17.43±2.02 (P=NS) and 23.99±3.38 vs 12.93±2.48 
(P<0.05) respectively. In brain tissues we found COX-2 immunoreactivity in a 
subset of neurons in normal as well as treated mice. In the treated mice, more 
cells showed an immunoreactivity which extended to degenerating neurons and 
blood vessels. Also in the kidney, we observed a strong COX-2 staining 
primarily in the glomeruli (Figure 4.19). Similarily, the anti-nitrotyrosine 
antibody stained neurons of the treated mice, while we saw only weak staining 
in the control group. Also in the kidney the immunostainig of the glomeruli was 





Figure 4.19: Histologic and immunohistochemical findings of brain and kidneys in 
treated mice (IS column). (A) (1) Brain; normal tissue from control mouse. (2) Brain; 
neuronal pyknosis associated with mild satellitosis. (3) Kidney; normal tissue from 
control mouse. (4) Kidney; Atrophic glomeruli and severe vacuolar degeneration of 
tubules with proteinaceous amorphous material and hypereosinofilic concretions 
within lumen (arrows); Hematoxylin and Eosin (HE) stain. (B) (1) Brain; normal 
tissue from control mouse. (2) Brain; strong immunoreactivity for COX-2 antibody in 
degenerating neurons (arrows) from treated mouse. (3) Kidney; normal tissue from 
control mouse. (4) Kidney; strong immunoreactivity for COX-2 antibody in blood 
vessels of the glomeruli (arrows) from treated mouse. Immunohistochemistry (HRP-
method). (C) (1) Brain; normal tissue from control mouse. (2) Brain; the 
immunoreactivity with the anti-nitrotyrosine antibody is intensely detected in the 
neurons of a treated mice (arrows). (3) Kidney; normal tissue from control mouse. (4) 
Kidney; strong immunoreactivity in blood vessels of an atrophic glomerulus (arrow) 
from treated mouse. Immunohistochemistry (HRP-method). Data are from two 




4.19 IS increased ROS production in serum patients: effect of AST-120 
In preliminary experiments we evaluated the effect on ROS release in C6 cells 
treated with serum from CKD dialysed patients (kindly provided by Dr. B.R. Di 
Iorio Ospedale “A. Landolfi”-Solofra- AV). We report the effect of serum of 
six subjects: two healthy (H1, IS=2.32 μM; H2, IS=2.91 μM) and four CKD 
patients (pat.1, IS=8.44 μM; pat. 2, IS=70.74 μM; pat.3, IS=31.46 μM; pat.4 
IS=62.08 μM). Our results indicate that ROS release was significantly increased 
in C6 cells treated with CKD serum (pat.1,2,3,4) respect to human healthy 
serum (H; P<0.001 vs control; Figure 4.20). It is worth noting that, in any case 
it is observed a correlation in ROS production.  
AST-120 serum treatment significantly reduced ROS release from astrocytes 
and in presence of AST-120 any significant difference was observed ROS levels 















































































Figure 4.20: Effect of serum from CKD dialysed patients alone or in presence 
of AST on ROS production in C6 cells. *** denotes P<0.001 vs control. °°°, °° 







In this project, we provide evidence that IS can directly influence glial function 
and cause neuronal damage. Thus, implicating IS directly in the CKD associated 
cognitive functions. Cognitive impairment of CKD patients is one of the main 
complications, despite the pharmacological and dialytic treatments [126-127]. 
Oxidative stress and inflammation are crucial for the defence against infections, 
but they initiate a number of deleterious effects if not properly regulated [128]. 
Inflammatory response in CKD patients resulted impaired, also contributing to 
cardiovascular disease, and oxidative stress increases in parallel with the 
progression of CKD and correlates with the level of renal function and, 
therefore, also with IS levels [129]. Furthermore, the antioxidant systems are 
severely impaired in CKD patients and worsen progressively with the degree of 
renal failure [129]. Thus, the pharmacological manipulation of inflammation 
and the control of oxidative stress is of particular importance in uremic 
syndrome. 
In this study we reported that IS induces inflammatory mediators activation and 
oxidative stress in glial cells. Our observations point to specific pathways 
underlying the oxidative stress and inflammation induced by IS in glial cells: (i) 
activation of pro-inflammatory mediators (e.g. NO, cytokines, proinflammatory 
enzymes), (ii) AhR and NF-kB activation, (iii) NADPH oxidase activation and 
glutathione homeostasis, (iv) reduction of antioxidant response Nrf2-mediated 
(v) and inflammasome activation. Moreover, we find a direct link of IS to 
neuronal damage linking IS to neurotoxicity.  
NO is generated by NO synthases and plays a prominent role in controlling a 
variety of organ functions in the cardiovascular, immune, reproductive and 
nervous systems. iNOS normally is not present in the brain in youth but it can 




well as in the normal, aging brain [130]. Brain iNOS seems to contribute to the 
pathophysiology of many diseases that involve the central nervous system 
[130]. Our results indicate that IS increases NO production and iNOS expression 
in inflammatory condition in C6 cells. An interaction between iNOS and COX 
pathway represents an important mechanism for inflammatory response 
modulation. COX-2 is the inducible isoform of COX and it is rapidly expressed 
in several cell types in response to growth factors, cytokines, and pro-
inflammatory molecules and that is responsible for the formation of prostanoids 
[131]. COX-2 over-expression has been associated with neurotoxiticy in acute 
conditions, such as hypoxia/ischemia and seizures, as well as in inflammatory 
chronic diseases in the CNS [131]. In our experiment we observed that IS 
increases COX-2 expression in presence of LPS+IFN in C6 cells. Inflammation 
is also characterized by cytokines production. TNF-α is a proinflammatory 
cytokine that exerts both homeostatic and pathophysiological roles in the CNS 
[132]. In pathological conditions, microglia release large amounts of TNF-α; 
this de novo production of TNF-α is an important component of the so-called 
neuroinflammatory response that is associated with several neurological 
disorders; in fact scientific evidence identifying TNF-α involvement in the 
pathogenesis of neurodegenerativ disease [132]. Our results indicate that IS 
enhances TNF-α release in inflammatory conditions in C6 cells. 
NF-κB is an inducible transcription factor present in neurons and glia. NF-κB 
can regulate the transcription of genes such as chemokines, cytokines (e.g. TNF-
α), proinflammatory enzymes (e.g. iNOS and COX-2), adhesion molecules, 
proinflammatory transcription factors, and other factors to modulate the 
neuronal survival [133]. In our experimental model IS enhances the 
phosphorylation and nuclear translocation of the p65 NF-kB subunit thus 
enhancing NF-kB activity in astrocytes. These results are in accordance with 
studies reporting the effect of IS in stimulating NF-kB pathway in endothelial 




the brain, AhR is ubiquitously expressed in areas including the cerebral cortex, 
hippocampus, and cerebellum [136]. AhR has been implicated in sensorimotor 
and cognitive dysfunctions caused by oxidative stress or excitotoxicity in 
neurons [136-138]. Moreover has been reported an AhR-mediated vascular 
inflammation in patients with renal disease [139]. Our results indicate that IS 
activates AhR in astrocytes which likely promotes further inflammation by AhR 
activation. It has been reported that NF-kB is able to activate AhR and to induce 
the inflammatory response [140]. In particular our data indicate also a cross-talk 
between NF-kB and AhR because on one hand PDTC, an NF-kB inhibitor, was 
able to reduce AhR activation and on other CH-223191, an AhR inhibitor, was 
able to interfere with NF-kB nuclear translocation, induced by IS, in our 
experimental model. NF-kB also primes the NLRP3-inflammasome for 
activation by inducing pro-IL-1β and caspase-1 expression [141]. The NLRP3 
(NLR family, pyrin domain-containing 3) inflammasome is a multiprotein, 
cytoplasmic complex, composed of a NLR protein, the adaptor ASC and 
procaspase-1, which regulates processing and secretion of cytokines belonging 
to the IL-1 family. In particular, NLRP3 inflammasomes have been shown to 
have a role in the etiologies of several neurological diseases such as depression 
[132], AD [143], PD [144]. Our results showed that IS increased caspase-1 
expression and IL-1β release in C6 in inflammatory conditions, thus indicating 
its effect in the inflammasome activation.  
The brain is a major metabolizer of oxygen and yet has relatively feeble 
protective antioxidant mechanisms. ROS are produced by various enzymatic 
reactions and chemical processes, which are essential for many physiological 
functions and act as second messengers. An increase in oxidative and 
nitrooxidative stress and a decrease in the antioxidant capacity of the brain are 
key factors involved in the pathogenesis of neurodegenerative diseases [15]. 
Under pathological conditions, increasing ROS production can regulate the 




Moreover, it has been reported that NAD(P)H oxidase increases in CKD 
patients and in experimental models of renal insufficiency [145,146]. We find 
that IS induces a significant and concentration-related ROS release from 
cultured C6 astrocytes. Mechanistic studies revealed that in IS-induced ROS 
release are involved both NADPH oxidase, as assessed by the presence of DPI, 
and glutathione homeostasis, as assessed by the presence of NAC. These results 
are in accordance with previous studies reporting that IS induces oxidative stress 
by interfering both with pro- and anti-oxidant factors in endothelial cells 
[147,148], vascular smooth muscle cells [149], kidney cells [150] and 
macrophages [114].  
IS-induced ROS has been reported to induce NF-kB activation. This activation 
could be, in turn, responsible for the Nrf2 downregulation [151], because of the 
interaction of p65 with Keap1 promotes reduction of Nrf2 protein level through 
Nrf2 ubiquitination [152] and the upregulation of p53 expression induced by IS-
induced NF-κB activation is involved in the suppression of Nrf2 mRNA 
expression [153]. We find that in IS reduced Nrf2 activation and HO-1 and 
NQO1 expression, thus further contributing to a decrease of antioxidant 
defences and then to oxidative stress conditions.  
Astrocytes are the most abundant glial cells in the CNS and they have a number 
of important physiological properties related to the homeostatic control of the 
extracellular environment. Astrocyte cells provide structural, trophic and 
metabolic support to neurons, modulate synaptic activity and are involved in 
multiple brain functions contributing to neuronal development. Moreover, 
astrocytes actively participate in processes triggered by brain injuries, aimed at 
repairing brain damage [154,155]. It has been recently reported that astrocytes 
contribute actively to various forms of dementia [156] and disturbances in the 
complex neuron–glia interaction are increasingly recognized as an important 
pathophysiological mechanism in a wide variety of neurological disorders 




In response to a variety of stimuli and pathological events astrocytes and 
microglia become activated. Microglia, activated earlier than astrocytes, 
promote astrocytic activation by releasing inflammatory mediators and ROS. 
On the other hand, activated astrocytes facilitate activation of distant microglia, 
and in some cases also inhibit microglial activities [158,159,22]. Thus, 
atrocytes-microglia interactions are important in regulating both physiological 
and pathological conditions. We could demonstrate that in mixed glial cell 
cultures stimulation with IS resulted in higher levels of ROS and 
proinflammatory mediators. Moreover the observed effects resulted further 
increased in mixed glial cells respect to primary astrocytes alone thus 
highlighting the higher neurotoxic IS potential on all the glial cells population. 
Activated microglia and astrocytes also release a variety of cytokines, 
chemokines and toxic factors, such as TNF-α, IL-6, and NO, all of which may 
lead to neuronal toxicity, result in the aggressive neuronal apoptosis, that has 
been reported as the most crucial events in neuronal loss of neurological 
diseases [160-163]. It has been also observed that IS can also affected cell 
viability and cycle distribution, increasing the G0/G1 and S phases and 
decreasing G2 phase in C6 cells and in astrocytes and in mixed glial cells. In 
this study we observed that IS increased neuronal cell death in cortical and 
hippocampal neurons thus causing an increase in neuronal death. Evidences of 
IS-induced effects on CNS are supported by in vivo experiments. IS induced 
histological brain alterations and the expression of oxidative stress and 
inflammatory markers, such as nitrotyrosine and COX-2. 
These results further highlight he effect of IS on CNS homeostasis. Our results 
add to hypothesis that IS significantly contributes to neurological complication 
observed in CKD. Moreover preliminary data on the effect of CKD serum 
patients on ROS release in C6 cells, indicate that, among the toxins present in 
serum from CKD patients, IS significantly contributes to oxidative stress in 




and add to hypothesis that IS significantly contributes to neurological 
complication observed in CKD. In conclusion we can hypothesize a significant 
role of IS in CKD-associated cognitive dysfunction thus highlighting its 
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